Current status of cancer immunotherapy for esophageal squamous cell carcinoma
Authors:
- 27 November 2017
- journal article
- review article
- Published by Springer Nature in Esophagus
- Vol. 15 (1) , 1-9
Abstract
Immunotherapy has become a promising treatment strategy for cancer. Immune checkpoint blockade with anti-CTLA4 mAb and anti-PD-1 mAb has demonstrated clear evidence of objective responses including improved overall survival and tumor shrinkage, driving renewed enthusiasm for cancer immunotherapy in multiple cancer types including esophageal squamous cell carcinoma (ESCC). There are several clinical trials using anti-PD1 mAb for ESCC in early phases and the results are currently promising.Keywords
This publication has 51 references indexed in Scilit:
- Comprehensive Registry of Esophageal Cancer in Japan, 2010Esophagus, 2017
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trialThe Lancet Oncology, 2017
- Immunotherapy for Esophageal Squamous Cell CarcinomaCurrent Oncology Reports, 2017
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThe Lancet Oncology, 2013
- The integration of T cell migration, differentiation and functionNature Reviews Immunology, 2013
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensJournal of Translational Medicine, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalitiesThe Lancet Oncology, 2007
- T-cell-antigen recognition and the immunological synapseNature Reviews Immunology, 2003